Skip to content

Advertisement

BMC Cancer

Research article
Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines

  • Rosalba D’Alessandro1,
  • Maria G Refolo1,
  • Catia Lippolis1,
  • Grazia Giannuzzi2,
  • Nicola Carella1,
  • Caterina Messa1,
  • Aldo Cavallini1 and
  • Brian I Carr1Email author
BMC Cancer201414:351

https://doi.org/10.1186/1471-2407-14-351

©  D’Alessandro et al.; licensee BioMed Central Ltd. 2014

Received: 30 December 2013

Accepted: 19 May 2014

Published: 21 May 2014

Open Peer Review reports

Abstract

Background

Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists.

Methods

Several human HCC cell lines were grown in the presence and absence of Sorafenib or Regorafenib, with or without hPL. Growth was measured by MTT assay, apoptosis was assessed by Annexin V and by western blot, and autophagy and MAPK growth signaling were also measured by western blot, and migration and invasion were measured by standard in vitro assays.

Results

Both Sorafenib and Regorafenib-mediated inhibition of cell growth, migration and invasion were all antagonized by hPL. Drug-mediated apoptosis and decrease in phospho-ERK levels were both blocked by hPL, which also increased anti-apoptotic phospho-STAT, Bax and Bcl-xL levels. Preliminary data, obtained with epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I), included in hPL, revealed that these factors were able to antagonized Sorafenib in a proliferation assay, in particular when used in combination.

Conclusions

Platelet factors can antagonize Sorafenib or Regorafenib-mediated growth inhibition and apoptosis in HCC cells. The modulation of platelet activity or numbers has the potential to enhance multikinase drug actions.

Keywords

RegorefenibPlateletsHCCApoptosisGrowthInvasion

Background

Platelet activity has been known for a long time to be altered in the presence of cancer, with venous thrombosis being recognized in association with occult malignancy [1, 2]. In addition to the effects of cancer on platelet actions in blood clotting, platelets have been recognized to be involved in cancer development, progression and metastasis [3–8]. Platelet levels have been shown to impact prognosis in several cancers, including those of the ovary, kidney, colon, lung and pancreas [9–14]. Furthermore, whereas hepatocellular carcinoma (HCC) most typically arises on the basis of cirrhosis, with its frequently associated splenomegaly and thrombocytopenia, normal or elevated platelet levels are frequently seen in large size HCCs [15–17]. We recently found that platelet extracts can stimulate HCC cell line growth in vitro, which was associated with a decrease in apoptosis [18]. We now extend those observations, by examining the effects of platelet extracts on the effects of apoptosis-inducing HCC treatment agents and report that platelet extracts can antagonize growth inhibition mediated by Sorafenib or Regorafenib.

Methods

Cells and materials

PLC/PRF/5, Hep3B and HepG2 cells were obtained from the ATCC and were cultured as previously described [19].

Recombinant human EGF was purchased from PeproTech (Rocky Hill, NJ, USA), mouse recombinant IGF-I from Calbiochem (San Diego, CA, USA) and serotonin from Sigma-Aldrich (Saint Louis, MO, USA), all the growth factors were dissolved in water.

Platelet lysates

The platelet samples were collected from healthy volunteers. The study protocol was approved by the institutional review boards of the University of Bari and “Saverio de Bellis” Institute of Castellana G. (BA), Italy. Additionally, written informed consent was obtained from participants for the use of their blood in this study.

The platelet-rich plasma was obtained using an automated hemapheresis procedure in a local blood transfusion center. The platelets obtained from different volunteers were mixed and then divided into aliquots. Each aliquot was subjected to several freeze-thaw cycles to disrupt their membranes and release the growth factors stored in the granules (human Platelet Lysate, hPL).

Growth assay

Proliferation assay was performed as recently described [19, 20]. The cells were cultured in 1% FBS medium containing different hPL concentrations (2.5 - 3.75 × 107) or equivalent percentage of FBS in presence of 1 μM (HepG2 cell line) or 2.5 μM (Hep3B and PLC/RFP/5) of Sorafenib or Regorafenib. In the same growth condition HCC cell lines were cultured in presence of EGF 10, 25 mg/ml, IGF-I 50, 100 mg/ml and serotonin 1, 10 μM with or without Sorafenib 1 μM.

AFP measurement

Medium AFP levels were measured using an automated system (UniCel Integrated Workstations DxC 660i, Beckman Coulter, Fullerton, CA, USA) by a chemoluminescent immunometric method. Sample measurements over the calibration range were automatically re-analyzed according to manufacture’s instructions.

Migration assay

A scratch assay was performed as previously described [19, 20]. Briefly, a wound was generated with a pipette tip, after rinsing, medium containing different concentrations of hPL or equivalent percentage of FBS and 2.5 μM Sorafenib or Regorafenib was added. Photographs were taken of each well immediately and after 24 h and 48 h. The values were expressed as percentage of migration, with 100% being when the wound was completely closed. The results were representative of three independent experiments.

Invasion assay

Cell invasion assays were performed using Matrigel (BD Transduction, San Jose, CA, USA)-coated Transwells (8 μm pore PET membrane, Millipore, Billerica, MA, USA) as previously described (19). Briefly, 2.5 μM Sorafenib or Regorafenib treated cells were suspended in low serum medium. Medium containing different hPL or FBS concentrations was added to the bottom wells. After incubation of 24 h, the invading cells were fixed and stained. The images were acquired and analyzed counting the cells with Image J Software (National Institute of Health, USA). Values obtained were expressed as fold increase of invading cells, setting the cell counts of control cells as one. Results were representative of three independent experiments.

Apoptosis assays

Annexin V

The Muse Annexin V/Dead Cell Assay Kit (Millipore, Darmstadt, Germany) for quantitative analysis of live, early/late apoptotic and dead cells was used with a Muse Cell Analyzer (Millipore). Briefly, the assay utilizes Annexin V to detect PS on the external membrane of apoptotic cells. A dead cell marker (7-AAD) is also used. PLC/PRF/5 cell line, including positive and negative controls, were cultured in 1% FBS medium supplemented with a volume of hPL corresponding to 3.75 × 107 platelets/ml or with an equivalent percentage of serum (control cells) for 48 h. The cells were then processed as described in the user’s guide.

Caspase-3/7 quantitative measurements

The Muse Caspase-3/7 kit (Millipore) permits simultaneous evaluation of apoptotic status based on Caspase-3 and -7 activation and cellular plasma membrane permeabilization (cell death). The assay provides relative percentage of cells that are live, early/late apoptotic or dead. Cells were cultured as described above and processed according to the user’s guide.

Western blots

We analyzed the MAPK signaling and anti-apoptosis markers in Hep3B cells treated with 2.5 μM Sorafenib or Regorafenib and hPL by Western blot, as previously described [19, 20]. In brief, cells were washed twice with cold PBS and then lysed in RIPA buffer (Sigma-Aldrich, Milan; Italy). After quantization of protein concentration, equal amount of protein (50 μg) were resolved on SDS–PAGE and transferred to polyvinyldifluoride (PVDF) filters. The blots were blocked with 5% (w/v) nonfat dry milk for 2 h at room temperature and then probed with primary antibody overnight at 4°C.

The primary antibodies were directed against the following proteins: ERK and phospho-ERK (P-ERK), JNK and phospho-JNK (P-JNK), p38 and phospho-p38 (P-p38), STAT3 and phospho-STAT3 (Tyr705, Ser727) (P-STAT3), AKT and phospho-AKT (P-AKT), survivin, Bcl-xL, Bax, Bim and β-actin (Cell Signaling, Beverly, MA, USA). After three washes, incubation was followed by the reaction with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The immunoreactive bands were visualized and analyzed using the enhanced chemiluminescence detection reagents (Cell Signaling), according to the manufacturer’s instructions, and chemiluminescence detection system (ChemiDoc XRS apparatus and software, Bio-Rad).

Statistical analysis

GraphPad Prism 5.0 software (La Jolla, CA, USA) was used for all statistical analysis. Mann–Whitney nonparametric test was employed to assess the statistical significance of differences between two groups. For multiple comparisons was used one-way Anova test followed by appropriate post-test. P-values of <0.05 were considered statistically significant. All experiments were done in triplicate and data are presented as mean ± standard deviation (SD).

Results

Platelet factors antagonize drug-mediated inhibition of HCC cell growth

hPL were previously examined for the ability to stimulate human HCC cell line growth [18]. Hep3B, PLC/PRF/5 and HepG2 human HCC cell lines were treated in log phase growth with 1 μM (HepG2) - 2.5 μM (Hep3B and PLC/PRF/5) Regorafenib or Sorafenib, concentrations which are known to decrease in HCC cell proliferation [19].

Cells were also treated in the absence or presence of increasing concentrations of hPL. A significant increase of cell growth was detected in presence of hPL from 3.75 × 107 platelets in all the HCC cell lines, compared with treatments with Regorafenib or Sorafenib in presence of FBS. Figure 1A-F shows the time course of these effects on the three cell lines. In order to exclude a possible FBS effects on the observed antagonism of cell growth inhibition due to drug action, PLC/RFP/5 cells treated or untreated with 2.5 μM Regorafenib were cultured in different FBS concentrations (0-5%) for 48 h in presence or absence of hPL derived from 3.75 × 107 platelets.
Figure 1

Platelets antagonism of Sorafenib or Regorafenib mediated cell growth inhibition. Hep3B (A, B), PLC/PRF/5 (C, D) and HepG2 (E, F) cell lines were cultured in 1% FBS medium in presence of different platelet concentrations or FBS and incubated with 1–2.5 μM Sorafenib (A, C, E) or Regorafenib (B, D, F). MTT assay was assessed after 24-72 h. (G) MTT assay performed on PLC/RFP/5 cells treated or untreated with 2.5 μM Regorafenib and cultured in different FBS concentrations (0-5%) for 48 h in presence or absence of hPL derived from 3.75 × 107 platelets. (H) AFP levels in the cell culture medium of PLC/PRF/5 cell lines containing hPL or FBS after treatment with different Sorafenib concentrations. The results are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001.

Comparing the growth in these different conditions by MTT assay, it was clear that increasing the serum concentration more than 1% had not significant influence on PLTs antagonism (Figure 1G). Identical results were obtained with Sorafenib treatments (data not shown).

The concentrations of medium alpha-fetoprotein (AFP), an HCC cell growth marker, were also measured. We found that Sorafenib-mediated inhibition of AFP levels was also antagonized by the presence of hPL (Figure 1H).

Effects of platelet factors on cell signaling

Both Sorafenib and Regorafenib have previously been shown to cause a decrease in P-ERK levels, consequent on Raf inhibition. Here, we examined the effects of 2.5 μM Sorafenib or Regorafenib on P-ERK levels in Hep 3B cells in the absence or presence of hPL from 3.75 × 107 platelets. We found that hPL caused an increase in P-ERK levels, as well as for P-p38 and P-STAT3 (Ser and Tyr). By contrast, P-JNK levels were not modified by the presence or absence of hPL (Figure 2).
Figure 2

Platelet extracts counteract the inhibitory effects of Sorafenib. A representative Western blot of 2.5 μM Sorafenib action that inhibits RAF/MEK/ERK signaling in Hep3B cells (to the left of the figure). The same action had been observed by Regorafenib (data not shown). The presence of hPL from 3.75 × 107 platelets reduced drug effects (to the right) with an increase of P-ERK, P-p38, P-STAT3, consistent with the induction of cell proliferation. No changes were observed in the phosphorylation levels of JNK.

Platelet factor antagonism of drug-mediated inhibition of migration and invasion

Both Sorafenib and Regorafenib can inhibit both HCC cell migration and invasion through Matrigel membranes. Furthermore, hPL has been shown to stimulate cell motility [21]. We therefore added hPL to 2.5 μM concentrations of Sorafenib or Regorafenib that could inhibit both migration and invasion in Hep3B cells.

We found that hPL antagonized the inhibition by Sorafenib or Regorafenib on both migration and invasion (Figure 3A-C). Identical results were found for the other cell lines (data not shown).
Figure 3

Platelet antagonism of drug-mediated inhibition of migration and invasion. Hep3B cell line was cultured in 1% FBS medium in presence of different platelets concentrations or FBS and incubated with 2.5-5 μM Sorafenib (A, C) or Regorafenib (B, C). Results of cell migration (A, B) and invasion (C) were expressed as percentage of migration (100% representing the completely closed wound) and fold increase over control invading cell, respectively.

Platelet factor antagonism of drug-mediated induction of apoptosis

To evaluate the possible platelet factor mechanisms, we examined their effects on Sorafenib or Regorafenib–mediated apoptosis, since that is one major aspect of their growth-inhibitory actions.

The drug induced both an increase in Annexin V and activation of Caspase 3/7, two separated apoptosis markers. When hPL were also added to the cell medium together with drug, a pronounced and significant inhibition in apoptosis induction was found (Figure 4A-B). These results were confirmed at the protein level with an increase of survivin, Bcl-xL and P-AKT levels (anti-apoptotic factors) and a decrease of Bax and Bim levels (pro-apoptotic factors) in Hep3B cells treated with 2.5 μM Sorafenib or Regorafenib in presence of hPL from 3.75 × 107 platelets (Figure 4C).
Figure 4

Platelet extract antagonism of drug-mediated inhibition of apoptosis. Apoptosis assays. On the left are shown examples of the results obtained using the Muse Annexin V kit (A) or Caspase-3/7 kit (B) to evaluate the percentage of apoptotic PLC/PRF/5 Hep3B cells treated with 2.5 μM of Regorafenib (A-B) or Sorafenib (A) and cultured whit 3.75 × 107 hPL or equivalent FBS are expressed in the relative graph as the mean of three independent experiments. On the right the mean of three independent experiments is plotted in the relative graph. The results are expressed as mean ± SD. ***p < 0.0001. The anti-apoptotic effect of hPL was also evaluated at the molecular level (C). The representative Western blot shows Hep3B cells treated with 2.5 μM Sorafenib with and without hPL from 3.75 × 107 platelets. hPL caused increased levels of anti-apoptotic factors (survivin, Bcl-xL, P-AKT) and decreased levels of pro-apoptotic (Bax, Bim) factors.

EGF and IGF antagonize drug-mediated inhibition of HCC cell growth

HCC cell lines were cultured in 1% FBS in presence of different doses of serotonin (1, 10 μM), IGF (50, 100 mg/ml) and EGF (10, 25 mg/ml) alone and in combination. The effect on proliferation, evaluated by MTT assay after 48 h, was significant only with EGF, while serotonin and IGF were effective only when used in combination. Figure 5A shows the results obtained whit HepG2 cell line cultured as described above; in the graphs were plotted the effective combinations. When Sorafenib 1 μM was added to the growth factors treatments, IGF and EGF antagonized the drug inhibition of proliferation; also in this case the effect was higher when IGF and EGF were used in combination (Figure 5B).
Figure 5

EGF and IGF counteract the inhibitory effect of Sorafenib. HepG2 cell line was cultured in 1% FBS medium in presence of different concentrations of serotonin, EGF and IGF-I or equivalent FBS (A) or incubated with the same doses of growth factors in presence of 1 μM Sorafenib (B). MTT assay was assessed after 48 h. The results are expressed as mean ± SD. *p < 0.05; **p < 0.001; ***p < 0.0001.

Discussion

We report here for the first time, the antagonizing effects of platelet extracts on growth inhibition in several HCC cell lines, that was mediated by Sorafenib or Regorafenib. Both agents were similarly antagonized by hPL. Furthermore, the previously demonstrated inhibition of AFP secretion by these drugs, was also antagonized. A main consequence of each drug is a decrease in phospho-ERK levels, secondary to Raf inhibition. hPL antagonized this early consequence of the drug action, without change in ERK levels. There was also an early and strong antagonism of the previously noted inhibitory effects of drug on phospho-p38 levels [20], and similarly for the p38 downstream target, phospho-STAT3 (Tyr and Ser). These are important molecules in mediating cell proliferation and play a role in the induction of anti-apoptosis mediators. Both Sorafenib and Regorafenib are known to increase apoptosis in treated cells. We found that this apoptosis-induction was antagonized by addition of hPL to cells that were treated with each of these two agents, as measured by both annexin V and caspase 3/7 activation.

Consistent with our findings of increased phospho-STAT3 levels, we also found an increase in the levels of anti-apoptotic Bcl-xL and survivin and a decrease in the levels of pro-apoptotic Bim and Bax, consequent to hPL action.

Due to the important role of platelets in the metastasis mechanisms of many tumors [8, 21], we evaluated hPL for a possible role in stimulating cell migration or invasion. We founds that the extracts also antagonized drug-mediated inhibition of HCC cell migration and invasion on Matrigel-treated membranes. In other systems, the targeting of platelets or experimental decrease in their numbers has been shown to enhance cancer chemotherapy [22, 23].

Platelets are the source of multiple growth factors, cytokines and inflammatory mediators [6].

Included among them are EGF, IGF-I, fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and serotonin, the modulation of each having been shown to alter cancer chemotherapy sensitivity or resistance [24–30]. Preliminary data, obtained with several growth factors included in hPL, revealed interesting results using EGF and IGF-I. Both these factors were able to antagonized Sorafenib in a proliferation assay, in particular when used in combination. This growth induction was more evident than that observed in absence of drug, suggesting a specific interference of these growth factors with the inhibitory action of Sorafenib.

Interestingly, the clinical insulin modulator and diabetes drug, metformin [26] and the serotonin modulator Fluoxetine/Prozac that is used in depression treatment [29, 30], each alter chemotherapy sensitivity in cancer cells. Multiple pathways have been found to be involved in Sorafenib-mediated growth inhibition, especially apoptosis and autophagy [19, 31, 32] as well as others [33–37] and several cytokines, or cytokine modulators that are produced by platelets can modulate Sorafenib activity [38]. Since Sorafenib effects have been clinically modest, several approaches are under way to enhance its actions, either on its downstream targets, or by adding inhibitors of parallel pathways in combination therapies [39]. Given the large number of candidate factors in platelets, the identification of those responsible for drug resistance is just beginning. However, FGF, IGF1 and serotonin would seem to be promising possibilities.

The recent finding that platelet inhibitors reduce hepatitis B associated experimental HCC [40] has led to new interest in the use of aspirin and other platelet inhibitors in HCC prevention, as in colon cancer prevention [41]. Thrombocytosis has been shown to be a negative prognostic factor for renal, breast, ovary, pancreas and colon cancers. Therefore, the results from this paper might be applicable to those tumor types, especially to renal cancer, since Sorafenib is also FDA-approved for treatment of renal cancer.

Conclusion

The current results give support to the idea that platelet inhibitors might also be useful in the drug therapy of patients with unresectable HCC, provided their platelet levels and coagulation systems are normal.

Abbreviations

HCC: 

Hepatocellular carcinoma

hPL: 

Human Platelets lysate

PVT: 

Portal vein thrombosis

ERK: 

Extracellular signal-regulated kinase

JNK: 

c-Jun NH2-terminal kinase

STAT: 

Signal transducer and activator of transcription-3

WB: 

Western blot

MTT: 

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

BrdU: 

5-bromo-2′-deoxy-uridine

AFP: 

Alpha-fetoprotein

EGF: 

Epidermal growth factor

IGF-I: 

Insulin-like growth factor-I.

Declarations

Acknowledgements

This research was supported in part by NIH grant CA82723 (BIC) and by Ministry of Health of Italy. The content is solely the responsibility of the authors and does not necessarily represent the official views of either NIH or Italian Ministry of Health.

Authors’ Affiliations

(1)
Laboratory of Biochemistry, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Castellana Grotte, Italy
(2)
Transfusion Medicine Center, “S. Maria degli Angeli” Hospital, Putignano, Italy

References

  1. Trousseau A: Phlegmana alba dolens. Clinic Med de l’Hotel-Dieu. 1985, 3: 654-712.Google Scholar
  2. Levin J, Conley CL: Thrombocytosis associated with malignant disease. Arch Intern Med. 1964, 114: 497-500. 10.1001/archinte.1964.03860100079008.View ArticlePubMedGoogle Scholar
  3. Leslie M: Cell biology: beyond clotting: the powers of platelets. Science. 2010, 328: 562-564. 10.1126/science.328.5978.562.View ArticlePubMedGoogle Scholar
  4. Borsig L: The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008, 8: 1247-1255. 10.1586/14737140.8.8.1247.View ArticlePubMedGoogle Scholar
  5. Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011, 20: 576-590. 10.1016/j.ccr.2011.09.009.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Buergy D, Wenz F, Groden C, Brockmann MA: Tumor-platelet interaction in solid tumors. Int J Cancer. 2012, 130: 2747-2760. 10.1002/ijc.27441.View ArticlePubMedGoogle Scholar
  7. Bambace NM, Holmes CE: The platelet contribution to cancer progression. J Thromb Haemost. 2011, 9: 237-249. 10.1111/j.1538-7836.2010.04131.x.View ArticlePubMedGoogle Scholar
  8. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M: The platelet-cancer loop. Eur J Intern Med. 2013, 24: 393-400. 10.1016/j.ejim.2013.01.017.View ArticlePubMedGoogle Scholar
  9. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, et al: Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012, 366: 610-618. 10.1056/NEJMoa1110352.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009, 27: 5794-5799. 10.1200/JCO.2008.21.4809.View ArticlePubMedGoogle Scholar
  11. Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J: Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2012, 36: 192-200. 10.1007/s00268-011-1329-7.View ArticlePubMedGoogle Scholar
  12. Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H: Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013, 44: 293-304. 10.1007/s12029-013-9491-9.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Yu D, Liu B, Zhang L: Platelet count predicts prognosis in operable non-small cell lung cancer. Exp Ther Med. 2013, 5: 1351-1354.PubMedPubMed CentralGoogle Scholar
  14. Wang H, Gao J, Bai M, Liu R, Li H, Deng T, Zhou L, Han R, Ge S, Huang D, Ba Y: The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Platelets. 2013, doi:10.3109/09537104.2013.827782Google Scholar
  15. Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, Chiang JH, Chau GY, Lui WY, Lee CC, Chang FY, Lee SD: Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004, 10: 2472-2477.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Carr BI, Guerra V: Features of massive hepatocellular carcinomas. Eur J Gastroenterol Hepatol. 2013, doi:10.1097/MEG.0b013e3283644c49Google Scholar
  17. Carr BI, Guerra V: Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci. 2013, 58: 1790-1796. 10.1007/s10620-012-2527-3.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Carr BI, D’Alessandro R, Refolo MG, Lippolis C, Cavallini A, Messa C: Effects of Pheripheral Blood Platelets on HCC Cell Growth, Migration and Invasion. The Liver Meeting Proc. 2013, Boston, MA, USA: AASLDGoogle Scholar
  19. Carr BI, Cavallini A, Lippolis C, D’Alessandro R, Messa C, Refolo MG, Tafaro A: Fluoro- Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol. 2013, 228: 292-297. 10.1002/jcp.24148.View ArticlePubMedPubMed CentralGoogle Scholar
  20. D’Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI: Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol. 2013, 72: 869-877. 10.1007/s00280-013-2269-8.View ArticlePubMedGoogle Scholar
  21. Dashevsky O, Varon D, Brill A: Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer. 2009, 124: 1773-1777. 10.1002/ijc.24016.View ArticlePubMedGoogle Scholar
  22. Demers M, Wagner DD: Targeting platelet function to improve drug delivery. Oncoimmunology. 2012, 1: 100-102. 10.4161/onci.1.1.17962.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Demers M, Ho-Tin-Noé B, Schatzberg D, Yang JJ, Wagner DD: Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011, 71: 1540-1549. 10.1158/0008-5472.CAN-10-2038.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Song S, Wientjes MG, Gan Y, Au JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A. 2000, 97: 8658-8663. 10.1073/pnas.140210697.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Shen K, Cui D, Sun L, Lu Y, Han M: Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem. 2012, 113: 2086-2089. 10.1002/jcb.24080.View ArticlePubMedGoogle Scholar
  26. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG: Metformin: taking away the candy for cancer?. Eur J Cancer. 2010, 46: 2369-2380. 10.1016/j.ejca.2010.06.012.View ArticlePubMedGoogle Scholar
  27. Atzori F, Traina TA, Ionta MT, Massidda B: Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol. 2009, 4: 255-266. 10.1007/s11523-009-0123-z.View ArticlePubMedGoogle Scholar
  28. Kina S, Phonaphonh T, Liang F, Kuang H, Arasaki A, Arakaki K, Nakasone T, Sunakawa H: PDGFα receptor is a mediator for cisplatin-induced Met expression. Eur J Pharmacol. 2013, 699: 227-232. 10.1016/j.ejphar.2012.11.014.View ArticlePubMedGoogle Scholar
  29. Zhou T, Duan J, Wang Y, Chen X, Zhou G, Wang R, Fu L, Xu F: Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol. 2012, 33: 1299-1306. 10.1007/s13277-012-0377-4.View ArticlePubMedGoogle Scholar
  30. Peer D, Dekel Y, Melikhov D, Margalit R: Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004, 64: 7562-7569. 10.1158/0008-5472.CAN-03-4046.View ArticlePubMedGoogle Scholar
  31. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64: 7099-7109. 10.1158/0008-5472.CAN-04-1443.View ArticlePubMedGoogle Scholar
  32. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66: 11851-11858. 10.1158/0008-5472.CAN-06-1377.View ArticlePubMedGoogle Scholar
  33. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N: The Bcl-xL inhibitor, ABT- 737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology. 2010, 52: 1310-1321. 10.1002/hep.23836.View ArticlePubMedGoogle Scholar
  34. Galmiche A, Ezzoukhry Z, François C, Louandre C, Sabbagh C, Nguyen-Khac E, Descamps V, Trouillet N, Godin C, Regimbeau JM, Joly JP, Barbare JC, Duverlie G, Mazière JC, Chatelain D: BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res. 2010, 8: 1116-1125. 10.1158/1541-7786.MCR-10-0029.View ArticlePubMedGoogle Scholar
  35. Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N: Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012, 131: 548-557. 10.1002/ijc.26374.View ArticlePubMedGoogle Scholar
  36. Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC, Galmiche A: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer. 2012, 131: 2961-2969. 10.1002/ijc.27604.View ArticlePubMedGoogle Scholar
  37. Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B, Galmiche A: Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013, 133: 1732-4172. 10.1002/ijc.28159.View ArticlePubMedGoogle Scholar
  38. Liu Y, Liu A, Li H, Li C, Lin J: Celecoxib inhibits interleukin-6/interleukin-6 receptor- induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res (Phila). 2011, 4: 1296-1305. 10.1158/1940-6207.CAPR-10-0317.View ArticleGoogle Scholar
  39. Dai Y, Grant S: Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007, 67: 2908-2911. 10.1158/0008-5472.CAN-07-0082.View ArticlePubMedGoogle Scholar
  40. Sitia G, Iannacone M, Guidotti LG: Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013, 4: doi:S0168- 8278(13)00373-5Google Scholar
  41. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S: Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013, 309: 2563-2571. 10.1001/jama.2013.6599.View ArticlePubMedPubMed CentralGoogle Scholar

    42. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/351/prepub

Copyright

© D’Alessandro et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us